Loading organizations...
Key people at ZSX Medical, LLC.
ZSX Medical, LLC is a clinical-stage medical device company enhancing minimally-invasive surgery. Its Zip-stitch surgical closure system streamlines complex internal closures, making them faster for physicians. This innovation aims to reduce hospital costs and improve patient outcomes, establishing a new standard for surgical closure techniques.
Co-founded in 2009 by Dan Mazzucco, Ph.D., and Eric Rugart, the company leverages their combined expertise. Dr. Mazzucco, a biomechanical engineer, contributed over two decades in medical implant design. Mr. Rugart, from a medical supply background for the OB/GYN community, provided crucial insight into efficient minimally-invasive closure needs.
The Zip-stitch system initially targets surgeons performing vaginal cuff closure during laparoscopic hysterectomies. ZSX Medical envisions transforming internal surgical closures, aspiring to reinvent women's health surgery. Their mission focuses on empowering surgeons with advanced tools for effective operations, ultimately enhancing patient care and recovery.
Key people at ZSX Medical, LLC.
ZSX Medical, LLC is a privately held, clinical-stage medical device company based in Philadelphia, Pennsylvania, focused on improving minimally invasive surgery through its lead product, Zip-stitch, a surgical closure system.[1][2][3] Zip-stitch targets complex closures like vaginal cuff closure in laparoscopic hysterectomies, primarily serving surgeons and hospitals in women's health by making procedures faster, easier, cost-effective, and improving patient outcomes.[1][3] The company has raised approximately $2.3 million in funding, employs fewer than 25 people, and generates under $5 million in revenue, with recent momentum from completing the first stage of its FDA-approved ZIMS pivotal clinical study (10th case with 6-week follow-up) and bolstering its board.[1][3][5]
Founded in 2009, ZSX Medical emerged as a medical device developer addressing unmet needs in surgical closures, starting as a pre-clinical stage company.[5][6] Key leaders include Co-Founder and President/CEO Dan Mazzucco, who has guided recent clinical milestones, and Co-Founder Eric Rugart.[1][5] The idea for Zip-stitch stemmed from reinventing closure techniques, particularly for women's health procedures like hysterectomies, evolving from internal closure innovations to a platform of wound closure devices now in clinical testing after FDA IDE approval for the ZIMS study.[1][2][6] Early traction includes SBIR-related development and progression to clinical stages, with the company leveraging a lean in-house team and external partners.[1]
ZSX Medical rides the trend toward minimally invasive surgery in women's health, where demand for hysterectomy innovations addresses the 600,000+ annual U.S. procedures by reducing large-incision risks and costs amid rising healthcare efficiency pressures.[1] Timing aligns with FDA support for clinical studies and a medtech funding environment favoring cost-saving devices, amplified by post-pandemic focus on outpatient procedures and value-based care.[1][5] Market forces like surgeon shortages and closure challenges favor Zip-stitch's ease-of-use, potentially influencing ecosystems by enabling broader adoption of laparoscopic techniques and inspiring platform expansions in wound closure.[2]
ZSX Medical is poised to secure additional funding post-ZIMS first stage to complete trials and launch Zip-stitch, potentially disrupting hysterectomy closures and expanding its platform.[1] Trends like AI-assisted surgery and personalized medtech will shape growth, with regulatory tailwinds and board expertise accelerating market entry. Its influence could evolve from niche innovator to key player in cost-effective minimally invasive tools, tying back to its core mission of easier surgery for better outcomes—watch for commercialization milestones in 2026.[1][5]
